| Year | Title | Author(s) |
| 2025 |
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy
Cancers |
Gitareja, K Chelliah, SS Sanij, E Sandhu, S Kang, J Khot, A |
| 2025 |
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer
Cell Death Discovery |
Cerra, C Tancock, MRC Thio, N Koo, A Wong, A Cowley, KJ Varshney, S Willis, MO Simpson, KJ Bowtell, DDL Sanij, E Christie, EL Pearson, RB Kang, J Chan, KT |
| 2024 |
The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression
Frontiers In Cell And Developmental Biology |
Kang, J Gallucci, S Pan, JQ Oakhill, JS Sanij, E |
| 2024 |
ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia
Science Advances |
Behrens, K Brajanovski, N Xu, Z Viney, EM Dirago, L Hediyeh-Zadeh, S Davis, MJ Pearson, RB Sanij, E Alexander, WS Ng, AP |
| 2024 |
Targeting the ribosome to treat multiple myeloma
Molecular Therapy Oncology |
Maclachlan, KH Gitareja, K Kang, J Cuddihy, A Cao, YX Hein, N Cullinane, C Ang, CS Brajanovski, N Pearson, RB Khot, A Sanij, E Hannan, RD Poortinga, G Harrison, SJ |
| 2022 |
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy
Cancers |
Inderjeeth, AJ Topp, M Sanij, E Castro, E Sandhu, S |
| 2022 |
Cystathionine-beta-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation
Elife |
Zhu, HR Chan, KT Huang, XR Cerra, C Blake, S Trigos, AS Anderson, D Creek, DJ Wang, X Fu, CY Jana, M Sanij, E Pearson, RB Kang, J |
| 2021 |
Harnessing the Nucleolar DNA Damage Response in Cancer Therapy
Genes |
Xuan, JC Gitareja, K Brajanovski, N Sanij, E |
| 2021 |
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Signal Transduction And Targeted Therapy |
Kang, J Brajanovski, N Chan, KT Xuan, JC Pearson, RB Sanij, E |
| 2021 |
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition
Molecular Cancer Therapeutics |
Lawrence, MG Porter, LH Choo, N Pook, D Grummet, JP Pezaro, CJ Sandhu, S Ramm, S Luu, J Bakshi, A Goode, DL Sanij, E Pearson, RB Hannan, RD Simpson, KJ Taylor, RA Risbridger, GP Furic, L |
| 2021 |
The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function
Nature Cell Biology |
Koltowska, K Okuda, KS Gloger, M Rondon-Galeano, M Mason, E Xuan, JC Dudczig, S Chen, HJ Arnold, H Skoczylas, R Bower, NI Paterson, S Lagendijk, AK Baillie, GJ Leshchiner, I Simons, C Smith, KA Goessling, W Heath, JK Pearson, RB Sanij, E Schulte-Merker, S Hogan, BM |
| 2020 |
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Nature Communications |
Sanij, E Hannan, KM Xuan, JC Yan, SF Ahern, JE Trigos, AS Brajanovski, N Son, J Chan, KT Kondrashova, O Lieschke, E Wakefield, MJ Frank, D Ellis, S Cullinane, C Kang, J Poortinga, G Nag, P Deans, AJ Khanna, KK Mileshkin, L McArthur, GA Soong, J Berns, EMJJ Hannan, RD Scott, CL Sheppard, KE Pearson, RB |